D-Index & Metrics Best Publications

D-Index & Metrics

Discipline name D-index D-index (Discipline H-index) only includes papers and citation values for an examined discipline in contrast to General H-index which accounts for publications across all disciplines. Citations Publications World Ranking National Ranking
Medicine D-index 89 Citations 33,639 637 World Ranking 6376 National Ranking 299

Overview

What is she best known for?

The fields of study she is best known for:

  • Cancer
  • Internal medicine
  • Breast cancer

Nadia Harbeck spends much of her time researching Internal medicine, Breast cancer, Oncology, Cancer and Surgery. Her work in Internal medicine covers topics such as Placebo which are related to areas like Bevacizumab and Aromatase inhibitor. Her Breast cancer study integrates concerns from other disciplines, such as Adjuvant therapy, Gynecology and Clinical trial, Pathology.

Her Oncology research includes themes of Plasminogen activator inhibitor-1, Trastuzumab, Mammary gland, Palbociclib and Clinical endpoint. Her Cancer research includes elements of Cancer research and Endocrinology. Her work deals with themes such as Adverse effect, General surgery and Breast disease, which intersect with Surgery.

Her most cited work include:

  • 2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial (1321 citations)
  • Palbociclib and Letrozole in Advanced Breast Cancer (940 citations)
  • Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer (820 citations)

What are the main themes of her work throughout her whole career to date?

Her primary scientific interests are in Internal medicine, Breast cancer, Oncology, Cancer and Chemotherapy. The study incorporates disciplines such as Gynecology and Surgery in addition to Internal medicine. Her Breast cancer research is multidisciplinary, relying on both Family medicine, Clinical trial, Disease and Docetaxel.

Nadia Harbeck works mostly in the field of Oncology, limiting it down to topics relating to Palbociclib and, in certain cases, Fulvestrant and Letrozole. Her studies in Cancer integrate themes in fields like Biomarker, Cancer research and Pathology. Her biological study spans a wide range of topics, including Gastroenterology, Triple-negative breast cancer and Anthracycline.

She most often published in these fields:

  • Internal medicine (68.49%)
  • Breast cancer (59.42%)
  • Oncology (56.23%)

What were the highlights of her more recent work (between 2019-2021)?

  • Internal medicine (68.49%)
  • Oncology (56.23%)
  • Breast cancer (59.42%)

In recent papers she was focusing on the following fields of study:

Nadia Harbeck focuses on Internal medicine, Oncology, Breast cancer, Cancer and Chemotherapy. Her work on Early breast cancer, Metastatic breast cancer, Endocrine therapy and Triple-negative breast cancer as part of her general Internal medicine study is frequently connected to In patient, thereby bridging the divide between different branches of science. Her Metastatic breast cancer study combines topics in areas such as Targeted therapy, Capecitabine and Phases of clinical research.

Her Oncology research integrates issues from Pembrolizumab, Abemaciclib, Trastuzumab and Adjuvant therapy. Her studies deal with areas such as Quality of life, Family medicine, Placebo, Hazard ratio and Gemcitabine as well as Breast cancer. Cancer is closely attributed to Mutation testing in her research.

Between 2019 and 2021, her most popular works were:

  • Pembrolizumab for Early Triple-Negative Breast Cancer. (228 citations)
  • Abemaciclib Combined With Endocrine Therapy for the Adjuvant Treatment of HR+, HER2−, Node-Positive, High-Risk, Early Breast Cancer (monarchE) (49 citations)
  • Clinical portrait of the SARS-CoV-2 epidemic in European cancer patients. (49 citations)

In her most recent research, the most cited papers focused on:

  • Cancer
  • Internal medicine
  • Breast cancer

Nadia Harbeck mostly deals with Internal medicine, Oncology, Breast cancer, Chemotherapy and Cancer. Her research investigates the connection between Internal medicine and topics such as Gastroenterology that intersect with issues in Hazard ratio and Placebo. Her Adjuvant study in the realm of Oncology interacts with subjects such as Vinorelbine.

Her Breast cancer research is multidisciplinary, incorporating elements of Gemcitabine and Clinical trial. Her Chemotherapy research incorporates elements of Taxane and Anthracycline. Her Cancer research is multidisciplinary, incorporating perspectives in Research design and Intensive care medicine.

This overview was generated by a machine learning system which analysed the scientist’s body of work. If you have any feedback, you can contact us here.

Best Publications

2-year follow-up of trastuzumab after adjuvant chemotherapy in HER2-positive breast cancer: a randomised controlled trial

Ian Smith;Marion Procter;Richard D Gelber;Sébastien Guillaume.
The Lancet (2007)

1800 Citations

Palbociclib and Letrozole in Advanced Breast Cancer

Richard S. Finn;Miguel Martin;Hope S. Rugo;Stephen Jones.
The New England Journal of Medicine (2016)

1472 Citations

Palbociclib in Hormone-Receptor–Positive Advanced Breast Cancer

Nicholas C. Turner;Jungsil Ro;Fabrice André;Sherene Loi.
The New England Journal of Medicine (2015)

1198 Citations

Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial

Massimo Cristofanilli;Nicholas C. Turner;Igor Bondarenko;Jungsil Ro.
Lancet Oncology (2016)

1179 Citations

Phase III Study of Bevacizumab Plus Docetaxel Compared With Placebo Plus Docetaxel for the First-Line Treatment of Human Epidermal Growth Factor Receptor 2–Negative Metastatic Breast Cancer

David W. Miles;Arlene Chan;Luc Y. Dirix;Javier Cortés.
Journal of Clinical Oncology (2010)

1161 Citations

Pooled analysis of prognostic impact of urokinase-type plasminogen activator and its inhibitor PAI-1 in 8377 breast cancer patients.

Maxime P. Look;Wim L. J. van Putten;Michael J. Duffy;Nadia Harbeck.
Journal of the National Cancer Institute (2002)

734 Citations

De-escalating and escalating treatments for early-stage breast cancer: the St. Gallen International Expert Consensus Conference on the Primary Therapy of Early Breast Cancer 2017.

G. Curigliano;H. J. Burstein;E. P. Winer;M. Gnant.
Annals of Oncology (2018)

714 Citations

ESO-ESMO 2nd international consensus guidelines for advanced breast cancer (ABC2)

F. Cardoso;A. Costa;L. Norton;E. Senkus.
Annals of Oncology (2014)

694 Citations

Triple-negative breast cancer—current status and future directions

O. Gluz;C. Liedtke;N. Gottschalk;L. Pusztai.
Annals of Oncology (2009)

616 Citations

Randomized adjuvant chemotherapy trial in high-risk, lymph node-negative breast cancer patients identified by urokinase-type plasminogen activator and plasminogen activator inhibitor type 1.

F. Janicke;A. Prechtl;C. Thomssen;N. Harbeck.
Journal of the National Cancer Institute (2001)

594 Citations

Editorial Boards

Breast Care
(Impact Factor: 2.268)

If you think any of the details on this page are incorrect, let us know.

Contact us

Best Scientists Citing Nadia Harbeck

Eleftherios P. Diamandis

Eleftherios P. Diamandis

Mount Sinai Hospital

Publications: 122

Michael Untch

Michael Untch

University of Miami

Publications: 108

Manfred Schmitt

Manfred Schmitt

Technical University of Munich

Publications: 107

Sibylle Loibl

Sibylle Loibl

Goethe University Frankfurt

Publications: 101

Giuseppe Curigliano

Giuseppe Curigliano

European Institute of Oncology

Publications: 99

Andreas Schneeweiss

Andreas Schneeweiss

German Cancer Research Center

Publications: 97

Peter A. Fasching

Peter A. Fasching

University of Erlangen-Nuremberg

Publications: 93

Javier Cortes

Javier Cortes

Vall d'Hebron Hospital Universitari

Publications: 88

Martine Piccart

Martine Piccart

Université Libre de Bruxelles

Publications: 78

Carsten Denkert

Carsten Denkert

Philipp University of Marburg

Publications: 78

Hope S. Rugo

Hope S. Rugo

University of California, San Francisco

Publications: 77

Eric P. Winer

Eric P. Winer

Harvard University

Publications: 74

Fatima Cardoso

Fatima Cardoso

Champalimaud Foundation

Publications: 73

Gunter von Minckwitz

Gunter von Minckwitz

University of Ulm

Publications: 71

José Baselga

José Baselga

Memorial Sloan Kettering Cancer Center

Publications: 69

Viktor Magdolen

Viktor Magdolen

Technical University of Munich

Publications: 66

Something went wrong. Please try again later.